Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years

Journal of Alzheimer's Disease

Volumn 12, Issue 3, 2007, Pages 255-260

  Zetterberg, Henrik ^a,b   Pedersen, Mona ^b   Lind, Karin ^b   Svensson, Maria ^b   Rolstad, Sindre ^b   Eckerström, Carl ^b   Syversen, Steinar ^b   Mattsson, Ulla Britt ^b   Ysander, Christina ^b   Mattsson, Niklas ^b   Nordlund, Arto ^b   Vanderstichele, Hugo ^c   Vanmechelen, Eugeen ^c   Jonsson, Michael ^b   Edman, Åke ^b   Blennow, Kaj ^b   Wallin, Anders ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c INNOGENETICS   (Belgium)

Author keywords

Alzheimer's disease; Amyloid (A ); Biomarkers; Cerebrospinal fluid; Longitudinal study; Mild cognitive impairment; Stability; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PHOSPHO TAU PROTEIN 181; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL;

EID: 36549078600     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2007-12307     Document Type: Article

References (28)

1. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, H. Vanderstichele, E. Vanmechelen and K. Blennow, Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease, Arch Neurol 56 (1999), 673-680.
2. American Psychatric Association, Diagnostic and Statistical Manual of Mental Disorders, Third edition, revised edn., American Psychiatric Association, Washington D.C., 1987.
3. R.J. Bateman, G. Wen, J.C. Morris and D.M. Holtzman, Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker, Neurology 68 (2007), 666-669.
4. K. Blennow, M.J. de Leon and H. Zetterberg, Alzheimer's disease, Lancet 368 (2006), 387-403.
5. K. Blennow, H. Zetterberg, L. Minthon, L. Lannfelt, S. Strid, P. Annas, H. Basun and N. Andreasen, Longitudinal stability of CSF biomarkers in Alzheimer's disease, Neurosci Lett 419 (2007), 18-22.
6. F.H. Bouwman, W.M. van der Flier, N.S. Schoonenboom, E.J. van Elk, A. Kok, P. Scheltens and M.A. Blankenstein, Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders, Clin Chem 52 (2006), 1604-1606.
7. C. DeCarli, Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, Lancet Neurol 2 (2003), 15-21.
8. T. Erkinjuntti, D. Inzitari, L. Pantoni, A. Wallin, P. Scheltens, K. Rockwood, G.C. Roman, H. Chui and D.W. Desmond, Research criteria for subcortical vascular dementia in clinical trials, J Neural Transm Suppl 59 (2000), 23-30.
9. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, A.R. Shah, G.N. LaRossa, M.L. Spinner, W.E. Klunk, C.A. Mathis, S.T. DeKosky, J.C. Morris and D.M. Holtzman, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann Neurol 59 (2006), 512-519.
10. M.F. Folstein, S.E. Folstein and P.R. McHugh, Mini-mental state, A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12 (1975), 189-198.
11. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
12. D.R. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg and K. Blennow, Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women, J Neurol Neurosurg Psychiatry 78 (2007), 461-464.
13. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow and L. Minthon, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol 5 (2006), 228-234.
14. S.K. Herukka, M. Hallikainen, H. Soininen and T. Pirttila, CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology 64 (2005), 1294-1297.
15. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, E. Vanmechelen and K. Blennow, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci Lett 297 (2001), 187-190.
16. M. Kanai, E. Matsubara, K. Isoe, K. Urakami, K. Nakashima, H. Arai, H. Sasaki, K. Abe, T. Iwatsubo, T. Kosaka, M. Watanabe, Y. Tomidokoro, M. Shizuka, K. Mizushima, T. Nakamura, Y. Igeta, Y. Ikeda, M. Amari, T. Kawarabayashi, K. Ishiguro, Y. Harigaya, K. Wakabayashi, K. Okamoto, S. Hirai and M. Shoji, Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan, Ann Neurol 44 (1998), 17-26.
17. T.A. Lanz, C.S. Himes, G. Pallante, L. Adams, S.Yamazaki, B. Amore and K.M. Merchant, The gamma-secretase inhibitor NN-( 3,5-difluorophenacetyl)-L- alanyl-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice, J Pharmacol Exp Ther 305 (2003), 864-871.
18. T.A. Lanz, J.D. Hosley, W.J. Adams and K.M. Merchant, Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl-N1-(7S)-5-methyl-6-oxo -6,7-dihydro-5Hdibenzob, dazepin-7-yl-L-alaninamide (LY-411575), J Pharmacol Exp Ther 309 (2004), 49-55.
19. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology 34 (1984), 939-944.
20. J.C. Morris, Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type, Int Psychogeriatr 9 Suppl 1 (1997), 173-176; discussion 177-178.
21. A. Nordlund, S. Rolstad, P. Hellstrom, M. Sjogren, S. Hansen and A. Wallin, The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition, J Neurol Neurosurg Psychiatry 76 (2005), 1485-1490.
22. A. Olsson, H. Vanderstichele, N. Andreasen, G. De Meyer, A. Wallin, B. Holmberg, L. Rosengren, E. Vanmechelen and K. Blennow, Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology, Clin Chem 51 (2005), 336-345.
23. E.R. Siemers, J.F. Quinn, J. Kaye, M.R. Farlow, A. Porsteinsson, P. Tariot, P. Zoulnouni, J.E. Galvin, D.M. Holtzman, D.S. Knopman, J. Satterwhite, C. Gonzales, R.A. Dean and P.C. May, Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease, Neurology 66 (2006), 602-604.
24. D. Strozyk, K. Blennow, L.R. White and L.J. Launer, CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, Neurology 60 (2003), 652-656.
25. L.J. Thal, K. Kantarci, E.M. Reiman, W.E. Klunk, M.W. Weiner, H. Zetterberg, D. Galasko, D. Pratico, S. Griffin, D. Schenk and E. Siemers, The role of biomarkers in clinical trials for Alzheimer disease, Alzheimer Dis Assoc Disord 20 (2006), 6-15.
26. L.O. Wahlund and K. Blennow, Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neurosci Lett 339 (2003), 99-102.
27. B. Winblad, K. Palmer, M. Kivipelto, V. Jelic, L. Fratiglioni, L.O. Wahlund, A. Nordberg, L. Backman, M. Albert, O. Almkvist, H. Arai, H. Basun, K. Blennow, M. de Leon, C. DeCarli, T. Erkinjuntti, E. Giacobini, C. Graff, J. Hardy, C. Jack, A. Jorm, K. Ritchie, C. van Duijn, P. Visser and R.C. Petersen, Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, J Intern Med 256 (2004), 240-246.
28. H. Zetterberg, M.A. Hietala, M. Jonsson, N. Andreasen, E. Styrud, I. Karlsson, A. Edman, C. Popa, A. Rasulzada, L.O. Wahlund, P.D. Mehta, L. Rosengren, K. Blennow and A. Wallin, Neurochemical aftermath of amateur boxing, Arch Neurol 63 (2006), 1277-1280.